SCHEMBL13310075

SCHEMBL13310075

COC(=O)[C@H](CC(C)C)NC(=O)Cc1ccc(Br)cc1Nc1ncnc2cc(OC)c(OC(C)=O)cc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 15/20 0.47
▸ EGFR P00533 6/20 0.47
▸ RET P07949 2/20 0.47
▸ KIF5B P33176 2/20 0.47
▸ HDAC3 O15379 12/20 0.44
▸ HDAC4 P56524 12/20 0.44
▸ HDAC1 Q13547 12/20 0.44
▸ HDAC7 Q8WUI4 12/20 0.44
▸ HDAC2 Q92769 12/20 0.44
▸ HDAC10 Q969S8 12/20 0.44
▸ HDAC11 Q96DB2 12/20 0.44
▸ HDAC8 Q9BY41 12/20 0.44
▸ HDAC6 Q9UBN7 12/20 0.44
▸ HDAC9 Q9UKV0 12/20 0.44
▸ HDAC5 Q9UQL6 12/20 0.44
▸ KDM4E B2RXH2 1/20 0.43
▸ GAK O14976 1/20 0.43
▸ MAPK13 O15264 1/20 0.43
▸ ABL1 P00519 1/20 0.43
▸ ERBB2 P04626 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13310076 0.90 KDR (0.45) KDREGFRRETKIF5BHDAC3
SCHEMBL13310077 0.89 HDAC3 (0.51) KDRHDAC3HDAC4HDAC1HDAC7
SCHEMBL20752920 0.81 KDR (0.51) KDREGFRHDAC3HDAC4HDAC1
SCHEMBL20752910 0.81 KDR (0.51) KDREGFRHDAC3HDAC4HDAC1
SCHEMBL20752914 0.81 KDR (0.51) KDREGFRHDAC3HDAC4HDAC1
SCHEMBL13310083 0.77 SRC (0.53) KDREGFRSRC
SCHEMBL535751 0.76 HDAC3 (0.48) KDREGFRRETKIF5BHDAC3
SCHEMBL13310085 0.76 AURKA (0.54) KDREGFRRETMAPTSRC
SCHEMBL535675 0.75 KDR (0.48) KDREGFRRETKIF5BHDAC3
SCHEMBL535716 0.75 KDR (0.48) KDREGFRRETKIF5BHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10208062-B2 Macrocyclic quinazole derivatives and their use as MTKI JANSSEN PHARMACEUTICA NV (BE) 2019-02-19 — — US disclosed
US-20170320894-A1 MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI JANSSEN PHARMACEUTICA NV (BE) 2017-11-09 — — US disclosed
US-9688691-B2 Macrocyclic quinazole derivatives and their use as MTKI JANSSEN PHARMACEUTICA NV (BE) 2017-06-27 — — US disclosed
US-20140256714-A1 MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI JANSSEN PHARMACEUTICA NV (BE) 2014-09-11 — — US disclosed
US-20100152174-A1 MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI JANSSEN-CILAG (FR) 2010-06-17 — — US disclosed
US-20100152174-A1 MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI JANSSEN-CILAG (FR) 2010-06-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256714-A1 MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI NR1I3, NR3C2, NR1I2 KDR 2610/4885EGFR 2929/4885RET 1558/4885
US-20100152174-A1 MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI NR1I3, NR1I2, NR3C2 KDR 2757/4885EGFR 2407/4885RET 1211/4885
US-20170320894-A1 MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI NR1I3, NR3C2, NR1I2 KDR 2610/4885EGFR 2929/4885RET 1558/4885
US-10208062-B2 Macrocyclic quinazole derivatives and their use as MTKI NR1I3, NR3C2, NR1I2 KDR 2610/4885EGFR 2929/4885RET 1558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback